Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: Pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea

Journal of Medicinal Chemistry

Volumn 39, Issue 26, 1996, Pages 5035-5046

  Adams, Jerry L ^a   Garigipati, Ravi S ^a   Sorenson, Margaret ^a   Schmidt, Stanley J ^a,b   Brian, William R ^a,c   Newton, John F ^a,c   Tyrrell, Kathy A ^a   Garver, Eric ^a   Yodis, Lee A ^a   Chabot Fletcher, Marie ^a   Tzimas, Maritsa ^a   Webb, Edward F ^a   Breton, John J ^a   Griswold, Don E ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Nycomed Inc   (United States)

^c Sanofi Winthrop Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SB 202235; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; DRUG ACTIVITY; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; ENANTIOMER; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BENZOFURANS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; HUMANS; LIPOXYGENASE INHIBITORS; MACACA FASCICULARIS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; STEREOISOMERISM; UREA;

EID: 0030463952     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960271d     Document Type: Article

References (38)

1. 4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J. Allergy Clin. Immunol. 1989, 84, 19-26.
2. (b) Lewis, R. A.; Austen, K. F.; Soberman, R. J. Leukotrienes and other products of the 5-lipoxygenase pathway. N. Engl. J. Med. 1990, 323, 645-655.
3. Henderson, W. R., Jr. Lipid-derived and other chemical mediators of inflammation in the lung. J. Allergy Clin. Immunol. 1987, 79, 543-553.
4. (a) Torphy, T. J.; Faiferman, I.; Gleason, J. G.; Hall, R. F.; Lewis, M. A.; Broom, C.; Helfrich, H. M.; Newton, J. F.; Hay, D. W. P. The preclinical and clinical pharmacology of SK&F 104353, a potent and selective peptidoleukotriene receptor antagonist. Ann. N.Y. Acad. Sci. 1991, 629, 157-167.
5. (b) Nakagawa, T.; Mizushima, Y.; Ishii, A; Nambu, F.; Motishi, M.; Yui, Y.; Shida, T.; Miyamoto, T. Effect of a leukotriene antagonist on experimental and clinical bronchial asthma. Adv. Prostaglandin, Thromboxane Leukotriene Res. 1990, 21, 465-468.
6. (c) Busse, W. W.; Gaddy, J. N. The role of leukotriene antagonists and inhibitors in the treatment of airway diseases. Am. Rev. Respir. Dis. 1991, 143, S103-S107.
7. Jewell, D. P.; Snook, J. A. Immunology of ulcerative colitis and Crohn's disease. In Inflammatory Bowel Diseases; Allan, R. N., Keighley, M. R. B., Alexander-Williams, J., Hawkins, C., Eds.; 1990, pp 127-146.
8. (a) Laursen, L. S.; Naesdal, J.; Bukhave, K.; Lauristen, K.; Rask-Madsen, J. Selective 5-lipoxygenase inhibition in ulcerative colitis. Lancet 1990,335, 683-685.
9. (b) Collawn, C.; Rubin, P.; Perez, N.; Bobadilla, J.; Cabrera, G.; Reyes, E.; Borovoy, J.; Kershenobich, D. Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis. Am. J. Gastroenterol. 1992, 87, 342-346.
10. Weinblatt, M. E.; Kremer, J. M.; Coblyn, J. S.; Helfott, S.; Maier, A. L.; Petrillo, G.; Hensen, B.; Rubin, P.; Sperling, R. Zileuton, A 5-lipoxygenase inhibitor in rhematoid arthritis. J. Rheumatol. 1992, 19, 1537-1541.
11. (a) Isreal, E.; Rubin, P.; Kemp, J. P.; Grossman, J.; Pierson, M. D.; Siegel S. C.; Tinkelman, D.; Murray, J. J.; Busse, W.; Segal, A. T.; Fish, J.; Kaiser, H. B.; Ledford, D.; Wenzel, S.; Rosenthal, R.; Cohn, J.; Lanni, C.; Pearlman, H.; Karahalios, P.; Drazen, J. M. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann. Intern. Med. 1993, 119 (11), 1059-1066.
12. (b) Friedman, B. S.; Bel, E. H.; Buntinx, A.; Tanaka, W.; Han, Y. H. R.; Shingo, S.; Spector, R.; Sterk, P. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am. Rev. Respir. Dis. 1993, 147 (4), 839-844.
13. (c) Crawley, G. C.; Bird, T. G. C.; Bruneau, P.; Dowell, R. I.; Edwards, P. N.; Foster, S. J.; Girodeau, J. M.; Mcmillan, R. M.; Walker, E. R. H.; Waterson, D. Structure and activity relationships leading to the discovery of ICI-D2138, a selective, potent and orally active inhibitor of 5-lipoxygenase. J. Lipid Mediators 1993, 6, 249-257.
14. (a) Carter, G. W.; Young, P. R.; Albert, D. H.; Bouska, J.; Dyer, R.; Bell, R. L.; Summers, J. B.; Brooks, D. W. 5-lipoxygenase inhibitory activity of zileuton. J. Pharmacol. Exp. Ther. 1991, 256, 929-937.
15. (b) Garland, L. G.; Salmon, J. A. Hydroxamic acids and hydroxyureas as inhibitors of arachidonate 5-lipoxygenase. Drugs Future 1991, 16 (6), 547-558.
16. Corey, E. J.; Cashman, J. R.; Kantner, S. S. Rationally designed, potent competitive inhibitors of leukotriene biosynthesis. J. Am. Chem. Soc. 1984, 106, 1503-1504.
17. (a) Falgueyret, J.-P.; Hutchinson, J. H.; Riendeau, D. Criteria for the identification of non-redox inhibitors of 5-lipoxygenase. Biochem. Pharmacol. 1993, 45, 978-981.
18. (b) Nelson, M. J.; Batt, D. G.; Thompson, J. S.; Wright, S. W. Reduction of the active-site iron by potent inhibitors of lipoxygenases J. Biol. Chem. 1991, 266, 8225-8229.
19. Summers, J. B., Jr. Lipoxygenase inhibiting compounds. Eur. Pat. Appl. 279281, 1987.
20. Shriner, R. L.; Grosser, F. Coumaran derivatives IX. Synthesis of 3,4,6,3′,4′-pentahydroxy-2-benzyl coumarin. J. Am. Chem. Soc. 1942, 64, 382-384.
21. Jung, M. E.; Abrecht, S. Improved synthesis of 3-substituted methoxybenzofurans, useful intermediates for preparation of morphine analogues. J. Org. Chem. 1988, 53, 4233-425.
22. Townsend, C. A.; Davis, S. G.; Christensen, S. B.; Link, J. C.; Lewis, C. P. Methoxymethyl-directed aryl metalation, a total synthesis of (±) averufin. J. Am. Chem. Soc. 1982, 103, 6885-6888.
23. Garigipati, R. S.; Sorenson, M. E.; Erhard, K. F.; Adams, J. L. Resolution of hydroxyureas. Tetrahedron Lett. 1993, 34, 5537-5540.
24. Casner, M. L.; Remers, W. A.; Bradner, W. T. Synthesis and biological activity of 6-substituted mitosene analogues of the mitomycins. J. Med. Chem. 1985, 28, 921-926.
25. Summers, J. B.; Gunn, B. P.; Martin, J. G.; Martin, M. B.; Mazdiyasni, H.; Stewart, A. O.; Young, P. R.; Bouska, J. B.; Goetze, A. M.; Dyer, R. D.; Brooks, D. W.; Carter, G. W. Structure-activity Analysis of a class of orally active hydroxamic acid inhibitors of leukotriene biosynthesis. J. Med. Chem. 1988, 31, 1960-1964.
26. Summers, J. B.; Kim, K. H.; Mazaditasni, H.; Holms, J. H.; Ratajeczyk, J. D.; Stewart, A. O.; Dyer, R. D.; Carter, G. W. Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J. Med. Chem. 1990, 33, 992-998.
27. Breton, J.; Keller, P.; Chabot-Fletcher, M.; Hillegass, L.; DeWolf, W., Jr.; Griswold, D. Use of a continuous assay of oxygen consumption to evaluate the pharmacology of 5-lipoxygenase inhibitors. Prostaglandins, Leukotrienes Essent. Fatty Acids 1993, 49, 929-937.
28. 4-production by stimulated human polymorphonuclear cells but not stimulated human whole blood. Biochem. Pharmacol. 1987, 36, 3529-3531.
29. Salmon, J. A.; Jackson, W. P.; Garland, L. G. Development and in vivo evaluation of 5-lipoxygenase inhibitors: potential drugs for asthma and inflammation. In Therapeutic Approaches to Inflammatory Diseases; Lewis, A. J., Doherty, N. S., Ackerman, N. R., Eds.; Elsevier Science Publishing Co.: New York, 1989; pp 137-146.
30. Tateson, J. E.; Randall, R. W.; Reynolds, C. H.; Jackson, W. P.; Bhattacherjee, P.; Salmon, J. A.; Garland, L. G. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo. Br. J. Pharmacol. 1988, 94, 528-539.
31. Griswold, D. E.; Hillegass, L. M.; White, J. R. Pharmacological evaluation of leukotriene biosynthesis and inflammation in an adoptive model of peritoneal anaphylaxis in the mouse. Drug Dev. Res. 1993, 30, 83-90.
32. Braeckman, R. A.; Granneman, G. R.; Rubin, P.; Kesterson, J. W. Pharmacokinetics and metabolism of the new 5-lipoxygenase inhibitor A-64077 after single oral administration in man. J. Clin. Pharmacol. 1989, 29, A22.
33. Sweeny, D. J.; Bouska, J.; Machinst, J.; Bell, R.; Caret, G.; Cepa, S.; Nellans, H. N. Glucuronidation of zileuton (A-64077) by human hepatic microsomes. Drug. Metab. Dispos. 1992, 20, 328-329.
34. A similar selection process to chose the prefered enantiomer of a racemic hydroxyurea has been described in the following: Bell, R. L.; Bouska, J. B.; Malo, P. E.; Lanni, C.; Harris, R. R.; Otis, E. R.; Stewart, A. O.; Brooks, D. W.; Carter, G. W. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors. J. Pharmacol. Exp. Ther. 1995, 272, 724-731.
35. The effects of SB 202235 in models of asthma and inflammation have recently been published. Chabot-Fletcher, M. C.; Underwood, D. C.; Breton, J. J.; Adams, J. L.; Kageysobotka, A.; Griswold, D. E.; Marshall, L. A.; Sarau, H. M.; Winkler, J. D.; Hay, D. W. P. Pharmacological characterization of SB-202235, a potent and selective 5-lipoxygenase inhibitor - Effects in Models of Allergic Asthma. J. Pharmacol. Exp. Ther. 1995, 273, 1147-1155.
36. A manuscript further detailing the chemistry and evaluation of additional analogues is currently in preparation and will address the clinical results with SB 202235.
37. Miyake, A.; Katsumi, I.; Norio, T.; Masao, T.; Hirata, M.; Oka, Y. Synthesis of 2-(N-Substituted amino)-6-hydroxy-1,2,3,4-tetra-hydronaphthalen-1-ol derivatives. Chem. Pharm. Bull. 1983, 31, 2329-2348.
38. Kim, K.; Kang, S.; Kim, I. K.; Hong, J. H. A Short synthesis of ethoproxyfen (MIT-500), a non-ester pyrethroid insecticide. Bull. Korean Chem. Soc. 1987, 8, 128.